Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NX-5948 by Nurix Therapeutics for Marginal Zone B-cell Lymphoma: Likelihood of Approval
NX-5948 is under clinical development by Nurix Therapeutics and currently in Phase I for Marginal Zone B-cell Lymphoma. According to...
NX-5948 by Nurix Therapeutics for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
NX-5948 is under clinical development by Nurix Therapeutics and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to...
NX-5948 by Nurix Therapeutics for Follicular Lymphoma: Likelihood of Approval
NX-5948 is under clinical development by Nurix Therapeutics and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...
NX-5948 by Nurix Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval
NX-5948 is under clinical development by Nurix Therapeutics and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...
NX-5948 by Nurix Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
NX-5948 is under clinical development by Nurix Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...
NX-1607 by Nurix Therapeutics for Epithelial Ovarian Cancer: Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...
NX-1607 by Nurix Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma...
NX-1607 by Nurix Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
NX-1607 by Nurix Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
NX-1607 by Nurix Therapeutics for Cervical Cancer: Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...
NX-1607 by Nurix Therapeutics for Gastric Cancer: Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
NX-1607 by Nurix Therapeutics for Peritoneal Cancer: Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase...
NX-1607 by Nurix Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...
NX-1607 by Nurix Therapeutics for Malignant Pleural Mesothelioma: Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Malignant Pleural Mesothelioma. According to GlobalData,...
NX-1607 by Nurix Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...
NX-1607 by Nurix Therapeutics for Fallopian Tube Cancer: Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...
NX-1607 by Nurix Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
NX-1607 by Nurix Therapeutics for Metastatic Melanoma: Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase...
NX-1607 by Nurix Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...
NX-1607 by Nurix Therapeutics for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According...